Featured Insight
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
On-Demand Webinar – SDOH and EHR – How are EHR vendors enabling providers’ efforts to close care gaps attributable to SDOH?
In this 1 hour live webinar, Precision experts Thad Nowakowski, Tim Van Aken, and Maureen Hennessey discuss the role that Social Determinants of Health plays in contributing to care gaps, current or proposed quality measures to support health equity, and how the top EHR vendors are enabling end user’s efforts to both capture SDOH variables, and act upon them to close care gaps.
On-Demand Webinar – Trends in Oncology: US Payer Management Considerations for 2022 and Beyond
In the last five years, 83 novel oncology substances have launched - oncology PMPM spend is now the highest among medical benefit categories, with 105% growth anticipated by 2024. As these numbers suggest, oncology is a key area of focus for payers, who are willing to invest resources to support appropriate utilization, but who struggle to keep up with the rapidly evolving science.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
A Focus on the Inflation Reduction Act
Curious how the healthcare provisions in the Inflation Reduction Act will impact your business? Start with this booklet by key experts from PRECISIONvalue where 5 experts weigh in on how the Inflation Reduction Act will affect payers in addition to 2023 trends, events, and developments in the payer world. Download the booklet.
White Paper: Achieving Launch Excellence: A Novel Data- and Analytics-Informed Approach
Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights. Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.
White Paper: 2022 and Beyond: How Key Legislative Events Will Impact the Payer Landscape
Interested in learning more about several legislative events shaping the managed care landscape in 2022 and beyond? Check out this insightful white paper, based on our recent webinar, which features insights from PRECISIONvalue’s expert Access Experience Team on various legislative proposals and payers’ potential responses to regulatory changes.
Download Now: Precision October Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision September Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
White Paper: Oncology Care in a Value-Based World
In this white paper, we explore the results of an exclusive Precision Value & Health survey on how payers and providers are adapting to—and supporting—the delivery of value-based care in an evolving oncology landscape.
Focus on Drug Prices Continues Amid Uncertainty Over Potential Changes
High prescription drug prices continue to be of concern at the federal level. Despite proposed changes to drug pricing policy by the administration and HHS, industry experts question whether any significant changes will occur in the near future. Precision's Ryan Cox and Erin Lopata weigh in on the factors contributing to the uncertainty about drug policy pricing changes.
What Do Employers Need to Know About Specialty Drugs?
Specialty drugs make up the bulk of the pharma pipeline. These drugs continue to come onto the market with higher and higher price tags, so employers should become more familiar with these therapies in order to properly manage them. Precision's Erin Lopata and Jorge Font weigh in on the other considerations beyond cost that employers need to know for managing specialty drugs.
Precision’s New HCEI/PIE Playbook Is Here!
As US healthcare costs continue to rise, Healthcare Economic Information (HCEI) and Pre-approval Information Exchange (PIE) are focal points of interest and developing a clearly-defined pre-launch communications strategy is more critical than ever.
Employers Have Variety of Approaches for High-Cost Drugs
As more high-cost drugs, including one-time gene therapies, come onto the market, employers are considering implementing a variety of contracting models to make sure their employees have access to these agents. Precision's Jorge Font and Erin Lopata explore these innovative new approaches, as well as the challenges in executing them.
Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers
As an increasing number of orphan drugs are FDA approved, health care payers, employers, and providers are attempting to strike a balance between patient access to innovative treatments and overall affordability. Precision's Erin Lopata, Christopher Terrone and Ami Gopalan and their co-authors review the results of a PRECISIONvalue and AMCP survey with payer, provider, and employer decision makers about their experiences and activities in the orphan disease space, including tactics to manage affordability of drugs to treat orphan diseases.
What You Need to Know About the Trump Administration’s Final Rule on Transparency in Coverage
The Administration's recently released final rule on transparency in healthcare coverage is set to take effect January 1, 2023. The rule aims to provide increased visibility into the cost of care for treatments and procedures and to support cost-conscious decisions about healthcare services. Precision's Erin Lopata provides an overview of what you need to know now.
Administration Issues Drug Pricing Rules That May Have Unintended Outcomes
Update on HHS drug pricing rules: An HHS final rule targeting Medicare Part D rebates was issued on November 30, 2020. Unlike the interim rule, the final rule includes only rebates in Part D, not Medicaid managed care, and it pushes back implementation from Jan. 1, 2020, to Jan. 1, 2022. Comments on the interim final rule following the Most Favored Nation model are due by Jan. 26, 2021. Precision's Andrew Cournoyer and Ryan Cox weigh in on the problems and concerns with both rules.
Unsurprisingly, COVID Pandemic and Race For Vaccine Led 2020 Pharma Headlines
The COVID-19 pandemic consumed most of 2020. While it was the big story last year, it wasn't the only story. Precision's Dan Danielson and other experts weigh in on the oversized impact of COVID-19 on the pharma industry, and other trends from 2020.
Contributor: How Payers Can Be Effective in New Value-Based Models for CKD
Value-based care has been replacing the traditional fee-for-service model in the United States. Value-based care models and population health are essential to improving health and reducing health care costs. Precision's Ryan Cox discusses how value-based payment models in chronic kidney disease can improve total cost and quality of care for patients.
MFN Rule Likely Will Have Broad Impact on Health Care System
An interim final rule that would require pricing drugs on the U.S. market based on their prices in certain countries is set to take effect on Jan. 1, 2021. Industry experts claim it will have little effect on bringing down prices for consumers. Precision's Ryan Cox joins other experts in discussing the far ranging impact of the new rule.
Real-World Evidence Has Crucial Role To Play in Race to COVID-19 Approvals
The trend of using real-world evidence (RWE) in the healthcare industry continues to grow. But perhaps it has never been more important than it is now during the current pandemic. Precisions Dan Danielson and others discuss the benefits to be gained from using RWE in the search for potential diagnostics, drugs and vaccines for COVID-19.
